Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2837.

DOI: https://doi.org/10.1182/blood-2021-147188

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

Andrew M. Brunner, Elie Traer, Norbert Vey, Sebastian Scholl, Natalia Tovar, Kimmo Porkka, Rupa Narayan, Guillermo Garcia-Manero, Steve Knapper, Martin Wermke, Jeroen J. Janssen, Jordi Esteve, Sun Loo, Mika Kontro, Zachariah Defilipp, Andrew H. Wei, Uma Borate

Blood (2021) 138 (Supplement 1): 3677.

DOI: https://doi.org/10.1182/blood-2021-151455

Published: 2021

Journal Articles

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

David F. Moreno, Sara Paz, Mari-Pau Mena, Monica Lopez-Guerra, Aina Oliver-Caldes, Anthony M Battram, Luis Gerardo Rodríguez-Lobato, Natalia Tovar, M. Teresa Cibeira, Raquel Jiménez-Segura, Joan Bladé Creixenti, Laura Rosinol, Dolors Colomer, Carlos Fernandez de Larrea

Blood (2021) 138 (Supplement 1): 462.

DOI: https://doi.org/10.1182/blood-2021-147168

Published: 2021

Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Blood (2021) 138 (Supplement 1): 244.

DOI: https://doi.org/10.1182/blood-2021-146039

Published: 2021

Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-136855

Published: 2020

Journal Articles

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Ignacio Isola, MD, David Moreno, MD, Esther Moga, MD PhD, Mari-Pau Mena, PhD, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, MD PhD, M. Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD, Carlos Fernandez de Larrea, MD PhD

Blood (2020) 136 (Supplement 1): 2–3.

DOI: https://doi.org/10.1182/blood-2020-139737

Published: 2020

Journal Articles

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Blood (2020) 136 (Supplement 1): 40–42.

DOI: https://doi.org/10.1182/blood-2020-137307

Published: 2020

Journal Articles

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 570.

DOI: https://doi.org/10.1182/blood-2019-128178

Published: 2019

Journal Articles

Smoldering Multiple Myeloma: Usefulness of Serum Heavy/Light Chain Measurements for the Evaluation of Evolving Pattern

Carlos Fernandez de Larrea, MD PhD, Ignacio Isola, MD, Esther Moga, Maria Teresa Cibeira, MD PhD, Ester Lozano, PhD, Juan I. Arostegui, Montserrat Elena, Natalia Tovar, MD PhD, Jordi Yague, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2018) 132 (Supplement 1): 4514.

DOI: https://doi.org/10.1182/blood-2018-99-117385

Published: 2018

Journal Articles

Natural History of Asymptomatic IgM Monoclonal Gammopathies: Impact of the Bone Marrow Aspiration into the Classification and Prognosis

Carlos Fernandez de Larrea, MD PhD, David Moreno, MD, Natalia Tovar, MD PhD, Maria Teresa Cibeira, MD PhD, Ignacio Isola, MD, Laura Magnano, MD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2018) 132 (Supplement 1): 1610.

DOI: https://doi.org/10.1182/blood-2018-99-115038

Published: 2018

Journal Articles

Survival Improvement in the Last 45 Years in Patients with Multiple Myeloma: Real-World Data from a Single Center

Luis Gerardo Rodríguez-Lobato, MD PhD, Carlos Fernández De Larrea, MD PhD, Natalia Tovar, MD PhD, Maria Teresa Cibeira, MD PhD, Joan Bladé, MD PhD, Laura Rosinol, MD PhD

Blood (2018) 132 (Supplement 1): 5573.

DOI: https://doi.org/10.1182/blood-2018-99-112089

Published: 2018

Journal Articles

Mir-485-3p and Mir-654-3p Expression in Bone Marrow Mesenchymal Stromal Cells in Patients with Monoclonal Gammopathies Is Related to the Status of the Disease

Carlos Fernandez de Larrea, MD PhD, Tania Diaz, PhD, Alfons Navarro, PhD, Ester Lozano, PhD, Mari-Pau Mena, PhD, Ignacio Isola, MD, Natalia Tovar, MD PhD, Maria Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2018) 132 (Supplement 1): 3155.

DOI: https://doi.org/10.1182/blood-2018-99-112222

Published: 2018

Journal Articles

Incidence and Outcome of Soft-Tissue Plasmacytomas in Patients with Multiple Myeloma before and after the Introduction of Novel Drugs

Raquel Jiménez, MD, Laura Rosinol, MD PhD, Maria Teresa Cibeira, MD PhD, Carlos Fernández De Larrea, MD PhD, Esther Blade, Natalia Tovar, MD PhD, Joan Bladé, MD PhD

Blood (2017) 130 (Supplement 1): 3140.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3140.3140

Published: 2017

Journal Articles

Bone Marrow Plasma Cell Infiltration in Light Chain Amyloidosis: Impact on Organ Involvement and Outcome

Carlos Fernandez de Larrea, MD PhD, Luis Gerardo Rodríguez-Lobato, MD, Natalia Tovar, MD PhD, Laura Magnano, MD, Ignacio Isola, MD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD, Mª Teresa Cibeira, MD PhD

Blood (2017) 130 (Supplement 1): 5365.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.5365.5365

Published: 2017

Journal Articles

Efficacy of Novel Agents on Soft-Tissue Plasmacytomas in Patients with Relapsed Multiple Myeloma

Raquel Jiménez-Segura, PhD, Carlos Fernández De Larrea, MD PhD, Maite Cibeira, MD PhD, Natalia Tovar, Esther Bladé, Ignacio Isola, MD PhD, Joan Bladé, Laura Rosiñol

Blood (2016) 128 (22): 5709.

DOI: https://doi.org/10.1182/blood.V128.22.5709.5709

Published: 2016

Journal Articles

BET Bromodomain Blockade Enhances Ikaros Inhibition By Lenalidomide Therapy Providing Additional Activity in I n Vitro and In Vivo Models of Multiple Myeloma

Carlos Fernández de Larrea, Tania Díaz, Vanina Rodriguez, Ester Lozano, Patricia Pérez-Galán, Mari-Pau Mena, Marcos Calderón, Laura Rosiñol, Antonio Martínez, MD PhD, Natalia Tovar, Gael Roue, Joan Bladé

Blood (2016) 128 (22): 308.

DOI: https://doi.org/10.1182/blood.V128.22.308.308

Published: 2016

Journal Articles

Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status

Carlos Fernández de Larrea, Xavier Calvo, Natalia Tovar, Ester Lozano, Xavier Setoain, Manel Juan, Tania Díaz, Laura Rosiñol, Montserrat Elena, Mª Teresa Cibeira, Ignacio Isola, Maria Rozman, Juan I. Aróstegui, Jordi Yagüe, Joan Bladé, MD

Blood (2015) 126 (23): 4192.

DOI: https://doi.org/10.1182/blood.V126.23.4192.4192

Published: 2015

Journal Articles

Salvage Therapy for Multiple Myeloma with Lenalidomide-Based Regimens: Impact of Single Nucleotide Polymorphisms Related to miRNA Pathways

Carlos Fernández de Larrea, MD PhD, Tania Díaz, PhD, María Teresa Cibeira, MD PhD, Natalia Tovar, MD, Alfons Navarro, PhD, Laura Rosiñol, MD PhD, Raquel Jiménez, MD, Rut Tejero, PhD, Mariano Monzó, MD PhD, Joan Bladé, MD PhD

Blood (2014) 124 (21): 2045.

DOI: https://doi.org/10.1182/blood.V124.21.2045.2045

Published: 2014

Journal Articles

Smoldering Multiple Myeloma: Impact of the Evolving Pattern on Early Progression

Carlos Fernández de Larrea, MD PhD, Ignacio Isola, MD, María Teresa Cibeira, MD PhD, Laura Rosiñol, MD PhD, Xavier Calvo, MD, Natalia Tovar, MD, Montserrat Elena, MD, Laura Magnano, MD, Juan I. Aróstegui, MD PhD, María Rozman, MD PhD, Jordi Yagüe, MD PhD, Joan Bladé, MD PhD

Blood (2014) 124 (21): 3363.

DOI: https://doi.org/10.1182/blood.V124.21.3363.3363

Published: 2014

Journal Articles

Prognostic Impact Of Serum Heavy/Light Chain Pairs In Patients With MGUS and Smoldering Myeloma: Long-Term Results From a Single Institution

Carlos Fernández de Larrea, MD, PhD, Laura Magnano, MD, Montserrat Elena, MD, María Teresa Cibeira, MD, PhD, Natalia Tovar, MD, Juan I. Aróstegui, MD, PhD, Fabiola Pedrosa, MS, Laura Rosiñol, MD, Xavier Filella, MD, PhD, Jordi Yagüe, MD, PhD, Joan Bladé, MD, PhD

Blood (2013) 122 (21): 3132.

DOI: https://doi.org/10.1182/blood.V122.21.3132.3132

Published: 2013

NARROW

Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma

Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Smoldering Multiple Myeloma: Usefulness of Serum Heavy/Light Chain Measurements for the Evaluation of Evolving Pattern

Natural History of Asymptomatic IgM Monoclonal Gammopathies: Impact of the Bone Marrow Aspiration into the Classification and Prognosis

Survival Improvement in the Last 45 Years in Patients with Multiple Myeloma: Real-World Data from a Single Center

Mir-485-3p and Mir-654-3p Expression in Bone Marrow Mesenchymal Stromal Cells in Patients with Monoclonal Gammopathies Is Related to the Status of the Disease

Incidence and Outcome of Soft-Tissue Plasmacytomas in Patients with Multiple Myeloma before and after the Introduction of Novel Drugs

Bone Marrow Plasma Cell Infiltration in Light Chain Amyloidosis: Impact on Organ Involvement and Outcome

Efficacy of Novel Agents on Soft-Tissue Plasmacytomas in Patients with Relapsed Multiple Myeloma

BET Bromodomain Blockade Enhances Ikaros Inhibition By Lenalidomide Therapy Providing Additional Activity in I n Vitro and In Vivo Models of Multiple Myeloma

Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status

Salvage Therapy for Multiple Myeloma with Lenalidomide-Based Regimens: Impact of Single Nucleotide Polymorphisms Related to miRNA Pathways

Smoldering Multiple Myeloma: Impact of the Evolving Pattern on Early Progression

Prognostic Impact Of Serum Heavy/Light Chain Pairs In Patients With MGUS and Smoldering Myeloma: Long-Term Results From a Single Institution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only